MX365219B - Uso de una composición en un método para inhibir el crecimiento del carcinoma de células escamosas de cabeza y cuello (hnscc). - Google Patents

Uso de una composición en un método para inhibir el crecimiento del carcinoma de células escamosas de cabeza y cuello (hnscc).

Info

Publication number
MX365219B
MX365219B MX2014001032A MX2014001032A MX365219B MX 365219 B MX365219 B MX 365219B MX 2014001032 A MX2014001032 A MX 2014001032A MX 2014001032 A MX2014001032 A MX 2014001032A MX 365219 B MX365219 B MX 365219B
Authority
MX
Mexico
Prior art keywords
hnscc
methods
function
compositions
neck cancer
Prior art date
Application number
MX2014001032A
Other languages
English (en)
Other versions
MX2014001032A (es
Inventor
Cong Le
Marie Egloff Ann
A Garraway Levi
Rubin Grandis Jennifer
S Lander Eric
Stransky Nicholas
D Tward Aaron
Zhang Feng
Original Assignee
The Broad Inst Inc Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Broad Inst Inc Star filed Critical The Broad Inst Inc Star
Publication of MX2014001032A publication Critical patent/MX2014001032A/es
Publication of MX365219B publication Critical patent/MX365219B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2999/00—Further aspects of viruses or vectors not covered by groups C12N2710/00 - C12N2796/00 or C12N2800/00
    • C12N2999/007—Technological advancements, e.g. new system for producing known virus, cre-lox system for production of transgenic animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a métodos relacionados con el tratamiento del carcinoma de células escamosas de cabeza y cuello (HNSCC) y de sus lesiones premalignas asociadas. En particular, la invención presenta métodos, los cuales pueden tener como objetivo específicamente los genes asociados con el HNSCC y alterar la expresión de los genes para tratar o aliviar los síntomas del HNSCC, o de sus lesiones premalignas asociadas. Estos métodos pueden involucrar la reducción de la función de un gen asociado con HNSCC con función de ganancia aberrante; o el aumento de la función de un gen asociado con HNSCC con pérdida de función aberrante.
MX2014001032A 2011-07-27 2012-07-25 Uso de una composición en un método para inhibir el crecimiento del carcinoma de células escamosas de cabeza y cuello (hnscc). MX365219B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512279P 2011-07-27 2011-07-27
PCT/US2012/048157 WO2013016434A1 (en) 2011-07-27 2012-07-25 Compositions and methods of treating head and neck cancer

Publications (2)

Publication Number Publication Date
MX2014001032A MX2014001032A (es) 2016-04-04
MX365219B true MX365219B (es) 2019-05-27

Family

ID=47601516

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001032A MX365219B (es) 2011-07-27 2012-07-25 Uso de una composición en un método para inhibir el crecimiento del carcinoma de células escamosas de cabeza y cuello (hnscc).

Country Status (4)

Country Link
US (1) US9370551B2 (es)
EP (1) EP2736538A4 (es)
MX (1) MX365219B (es)
WO (1) WO2013016434A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
US10801017B2 (en) * 2011-11-30 2020-10-13 The Broad Institute, Inc. Nucleotide-specific recognition sequences for designer TAL effectors
CA2880764C (en) * 2012-08-03 2022-08-30 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
US9944700B2 (en) 2013-03-13 2018-04-17 Novartis Ag Notch2 binding molecules for treating respiratory diseases
WO2014169810A1 (zh) * 2013-04-16 2014-10-23 深圳华大基因科技服务有限公司 分离的寡核苷酸及其用途
WO2015164748A1 (en) * 2014-04-24 2015-10-29 Sangamo Biosciences, Inc. Engineered transcription activator like effector (tale) proteins
US10040048B1 (en) 2014-09-25 2018-08-07 Synthego Corporation Automated modular system and method for production of biopolymers
EP4286847A3 (en) 2015-08-07 2024-07-03 Dana-Farber Cancer Institute, Inc. Genetic abnormalities in plasma cell dyscrasias
EP4036583A1 (en) 2017-08-11 2022-08-03 Board of Regents, The University of Texas System Targeting kinases for the treatment of cancer metastasis
EP4045649A4 (en) * 2019-10-15 2023-11-22 Altius Institute For Biomedical Sciences DNA-BINDING PROTEINS FOR SHIFTING ENDOGENE TRANSCRIPTION FACTORS LINKED TO GENE REGULATORY REGIONS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888121B2 (en) * 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
JP4988606B2 (ja) 2005-02-28 2012-08-01 サンガモ バイオサイエンシズ インコーポレイテッド 抗血管新生方法及び組成物
WO2008120831A1 (en) 2007-03-30 2008-10-09 Seoul National University Industry Foundation Dnp63a gene and screening methods of anticancer agent by using it
WO2009155659A1 (en) * 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
US8586526B2 (en) * 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
CN102770539B (zh) 2009-12-10 2016-08-03 明尼苏达大学董事会 Tal效应子介导的dna修饰
US9267123B2 (en) 2011-01-05 2016-02-23 Sangamo Biosciences, Inc. Methods and compositions for gene correction
US9499592B2 (en) * 2011-01-26 2016-11-22 President And Fellows Of Harvard College Transcription activator-like effectors

Also Published As

Publication number Publication date
EP2736538A1 (en) 2014-06-04
EP2736538A4 (en) 2015-08-05
WO2013016434A1 (en) 2013-01-31
MX2014001032A (es) 2016-04-04
US20130171124A1 (en) 2013-07-04
US9370551B2 (en) 2016-06-21
WO2013016434A8 (en) 2014-08-28

Similar Documents

Publication Publication Date Title
MX365219B (es) Uso de una composición en un método para inhibir el crecimiento del carcinoma de células escamosas de cabeza y cuello (hnscc).
WO2010138806A8 (en) Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
MX358603B (es) Tratamiento de enfermedades relacionadas con un gen supresor de tumor mediante inhibicion del transcrito antisentido natural para el gen.
MX2016016133A (es) Métodos y composiciones para modificar un locus dirigido.
WO2016109546A3 (en) Methods and compositions for prognosis and treatment of cancers
CL2015001790A1 (es) Compuestos derivados de 3,4-dihidroisoquinolina sustituidos, inhibidores de prmt5; composicion farmaceutica; kit farmaceutico; metodo de inhibicion de prmt5; metodo para tratar la expresion de un gen; metodo para alterar la transcripcion; metodo de tratamiento de un trastorno tal como cancer, diabetes y obesisdad, entre otros.
WO2015143046A3 (en) Methods and compositions for regulation of zinc finger protein expression
WO2011094483A3 (en) Immune gene signatures in cancer
WO2011103528A3 (en) Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
WO2011091390A3 (en) Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
EP3106168A3 (en) Targeting micrornas mir-409-5p, mir-379 and mir-154* to treat prostate cancer bone metastasis and drug resistant lung cancer
PH12015502855A1 (en) Peptides and petidomimetics in combination uses and treatments for cancer patient subpopulations
WO2011082409A3 (en) Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
WO2012009402A3 (en) Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
WO2011017516A3 (en) Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
WO2011088137A3 (en) Bad pathway gene signature
WO2013040436A3 (en) Esx-mediated transcription modulators and related methods
WO2011019815A3 (en) Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
WO2011123745A3 (en) Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
MX2016001439A (es) Composiciones y metodos para identificar un riesgo de cancer en un sujeto.
WO2011150007A3 (en) Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
WO2012071238A3 (en) Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
WO2012138789A3 (en) Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
WO2013120022A3 (en) Treatment of hypoglycemia
PH12014501554A1 (en) Compositions and methods for the expression of a sequence in a reproductive tissue of a plant

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: THE BROAD INSTITUTE, INC.*

FG Grant or registration